BACKGROUND: The use of niacin in the treatment of dyslipidemias is limited by the common side effect of cutaneous vasodilation, commonly termed flushing. Flushing is thought to be due to release of the vasodilatory prostanoids prostaglandin D2 (PGD2) and prostaglandin E2 from arachidonic acid metabolism through the cyclooxygenase pathway. Arachidonic acid is also metabolized by the cytochrome P450 system, which is regulated, in part, by the enzyme soluble epoxide hydrolase (sEH). METHODS: These experiments used an established murine model in which ear tissue perfusion was measured by laser Doppler to test the hypothesis that inhibition of sEH would limit niacin-induced flushing. RESULTS: Niacin-induced flushing was reduced from 506 ± 126% to 213 ± 39% in sEH knockout animals. Pharmacologic treatment with 3 structurally distinct sEH inhibitors similarly reduced flushing in a dose-dependent manner, with maximal reduction to 143% ± 15% of baseline flow using a concentration of 1 mg/kg TPAU (1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl) urea). Systemically administered PGD2 caused ear vasodilation, which was not changed by either pharmacologic sEH inhibition or sEH gene deletion. CONCLUSIONS: Inhibition of sEH markedly reduces niacin-induced flushing in this model without an apparent effect on the response to PGD2. sEH inhibition may be a new therapeutic approach to limit flushing in humans.
BACKGROUND: The use of niacin in the treatment of dyslipidemias is limited by the common side effect of cutaneous vasodilation, commonly termed flushing. Flushing is thought to be due to release of the vasodilatory prostanoidsprostaglandin D2 (PGD2) and prostaglandin E2 from arachidonic acid metabolism through the cyclooxygenase pathway. Arachidonic acid is also metabolized by the cytochrome P450 system, which is regulated, in part, by the enzyme soluble epoxide hydrolase (sEH). METHODS: These experiments used an established murine model in which ear tissue perfusion was measured by laser Doppler to test the hypothesis that inhibition of sEH would limit niacin-induced flushing. RESULTS:Niacin-induced flushing was reduced from 506 ± 126% to 213 ± 39% in sEH knockout animals. Pharmacologic treatment with 3 structurally distinct sEH inhibitors similarly reduced flushing in a dose-dependent manner, with maximal reduction to 143% ± 15% of baseline flow using a concentration of 1 mg/kg TPAU (1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl) urea). Systemically administered PGD2 caused ear vasodilation, which was not changed by either pharmacologic sEH inhibition or sEH gene deletion. CONCLUSIONS: Inhibition of sEH markedly reduces niacin-induced flushing in this model without an apparent effect on the response to PGD2. sEH inhibition may be a new therapeutic approach to limit flushing in humans.
Authors: Paul D Jones; Hsing-Ju Tsai; Zung N Do; Christophe Morisseau; Bruce D Hammock Journal: Bioorg Med Chem Lett Date: 2006-07-25 Impact factor: 2.823
Authors: Christophe Morisseau; Marvin H Goodrow; John W Newman; Craig E Wheelock; Deanna L Dowdy; Bruce D Hammock Journal: Biochem Pharmacol Date: 2002-05-01 Impact factor: 5.858
Authors: Ayala Luria; Steven M Weldon; Alisa K Kabcenell; Richard H Ingraham; Damian Matera; Huiping Jiang; Rajan Gill; Christophe Morisseau; John W Newman; Bruce D Hammock Journal: J Biol Chem Date: 2006-11-29 Impact factor: 5.157
Authors: Yuttana Chawengsub; Nitin T Aggarwal; Kasem Nithipatikom; Kathryn M Gauthier; Siddam Anjaiah; Bruce D Hammock; John R Falck; William B Campbell Journal: Am J Physiol Heart Circ Physiol Date: 2008-01-11 Impact factor: 4.733
Authors: John F Paolini; Yale B Mitchel; Robert Reyes; Uma Kher; Eseng Lai; Douglas J Watson; Josephine M Norquist; Alan G Meehan; Harold E Bays; Michael Davidson; Christie M Ballantyne Journal: Am J Cardiol Date: 2007-12-21 Impact factor: 2.778
Authors: Yurika Otoki; Adam H Metherel; Theresa Pedersen; Jun Yang; Bruce D Hammock; Richard P Bazinet; John W Newman; Ameer Y Taha Journal: Lipids Date: 2019-11-06 Impact factor: 1.880
Authors: Mattijs M Heemskerk; Harish K Dharuri; Sjoerd A A van den Berg; Hulda S Jónasdóttir; Dick-Paul Kloos; Martin Giera; Ko Willems van Dijk; Vanessa van Harmelen Journal: J Lipid Res Date: 2014-10-15 Impact factor: 5.922